What records are connected here?
- Evidence lanes
- 3
- Source years
- 17
- Drugs@FDA applications
- 32
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
FDA-approved1,2Evidence: Large human trialsSkin · Infections
Daptomycin is a cyclic lipopeptide antibiotic, a ring-shaped peptide with a fatty side chain, made by fermentation of the bacterium Streptomyces roseosporus. It is the active ingredient in Cubicin and Cubicin RF.1,2 FDA first approved it in 2003. The label covers complicated skin infections in adults and children aged 1 to 17, and Staphylococcus aureus bloodstream infections, including right-sided heart valve infection in adults.1,2 In two randomized trials in adults with complicated skin infections, cure rates were similar to standard comparator antibiotics. The label states that it is not indicated for pneumonia.1
| What it is | A cyclic lipopeptide antibacterial that binds bacterial cell membranes and collapses their electrical potential, which kills the bacteria, according to the label.1 |
|---|---|
| FDA status | FDA-approved. Drugs@FDA lists NDA 021572 with an original approval date of September 12, 2003. The cited label has no boxed warning.1,2 |
| Human evidence | Two randomized, investigator-blinded trials in about 1,092 adults with complicated skin infections and a randomized, open-label trial in 246 adults with S. aureus bloodstream infection, described in the label.1 |
| Evidence strength | Large randomized human trials. The cited sources include at least one fully reported randomized, controlled human trial with 300 or more participants, or a trial that a regulator cites as a basis for approval. How this label is assigned |
Daptomycin is a cyclic lipopeptide antibacterial agent derived from the fermentation of Streptomyces roseosporus, according to the label.1
Drugs@FDA lists Cubicin and Cubicin RF under application NDA 021572.2
The label states that daptomycin binds bacterial cell membranes and rapidly depolarizes them; the loss of membrane potential stops DNA, RNA and protein synthesis and kills the bacteria.1
In Study 9801, clinical success in all randomized patients was 62.5% with daptomycin and 60.9% with comparators; Study 9901 was a second randomized trial of the same design, according to the label.1
In a randomized, open-label trial of 246 adults with S. aureus bloodstream infection, success judged by a blinded committee six weeks after treatment was 44.2% with daptomycin and 41.7% with comparators, according to the label.1
The label reports that success was lower in adults with moderately reduced kidney function, and that outcomes in left-sided heart valve infection were poor.1
Evidence-strength label: Large randomized human trials. How this label is assigned
Yes. Drugs@FDA lists application NDA 021572, for Cubicin and Cubicin RF, with an original approval date of September 12, 2003.2
The Cubicin RF label cited here (DailyMed SPL version 22, published June 20, 2025) states that it is indicated for complicated skin and skin structure infections in adults and children aged 1 to 17, and for S. aureus bloodstream infections in adults, including right-sided infective endocarditis, and in children aged 1 to 17.1
The label has no boxed warning. It states that daptomycin is not indicated for pneumonia or for left-sided S. aureus endocarditis, and its warnings include muscle damage, eosinophilic pneumonia, severe drug reactions and nerve damage.1
Its effect in left-sided heart valve infection, for which the label states its trial data were limited and outcomes poor.1
Its safety in infants under 12 months, in whom the label advises against use because of possible effects on muscles and nerves.1
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Go deeper
Everything PeptideScanner has collected for Daptomycin: reviews, official-source readings, registry and literature records, and every change to this profile.
What the trial and literature lists cover. The trials and papers listed for Daptomycin are a bounded selection, not every registration or paper about Daptomycin. For the years before Daptomycin was added, PeptideScanner took at most 30 ClinicalTrials.gov registrations that list Daptomycin as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 30 PubMed papers that name Daptomycin in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.
Evidence summary
FDA-approved as Cubicin RF for skin infections and S. aureus bloodstream infections. Randomized trials described in the label found success rates similar to standard comparator antibiotics. The label states that it is not indicated for pneumonia.↗↗
Status sources checked through November 15, 2026. See status sources and coverage →
Explore this profile’s cited source records →
An editorial human-evidence summary has not yet been published.
Living status brief
FDA-approved as Cubicin RF for skin infections and S. aureus bloodstream infections. Randomized trials described in the label found success rates similar to standard comparator antibiotics. The label states that it is not indicated for pneumonia.↗↗
The cited status sources were checked through November 15, 2026. This answer changes only through the profile’s visible version and correction history.
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
Literature metadata · source date November 9, 2026
Daptomycin Plus Fosfomycin Versus Daptomycin Alone for Methicillin-resistant Staphylococcus aureus Bacteremia and Endocarditis: A Randomized Clinical Trial.↗Added to PeptideScanner November 15, 2026Literature metadata · added November 15, 2026
Daptomycin Plus Fosfomycin Versus Daptomycin Alone for Methicillin-resistant Staphylococcus aureus Bacteremia and Endocarditis: A Randomized Clinical Trial.↗Source date November 9, 2026Literature metadata · added November 15, 2026
Daptomycin for enterococcal bloodstream infections and endocarditis: reconciling clinical evidence, susceptibility testing, and regulatory frameworks.↗Source date October 13, 2026Literature metadata · added November 15, 2026
Clinical Pharmacokinetics of Daptomycin.↗Source date October 10, 2026PeptideScanner currently has no selected safety records connected to this profile. That is a collection gap, not evidence that no such records exist.
PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.
Evidence Map v1
This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.
30 of 30 selected trial records include at least one phase value; 30 of 30 include a status value in the retained structured contract.
30 of 30 selected PubMed records include attributed title, venue, publication date, and publication-type fields.
Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.
Research hub
PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.
PeptideScanner retained ClinicalTrials.gov record NCT00093067 at 2026-11-15T22:01:45.056Z. Its registry update date was 2017-02-13, and PeptideScanner's reviewed identity mapping was daptomycin.
PeptideScanner retained ClinicalTrials.gov record NCT00295178 at 2026-11-15T22:01:45.056Z. Its registry update date was 2017-09-07, and PeptideScanner's reviewed identity mapping was daptomycin.
PeptideScanner retained ClinicalTrials.gov record NCT00428844 at 2026-11-15T22:01:45.056Z. Its registry update date was 2018-01-31, and PeptideScanner's reviewed identity mapping was daptomycin.
30 with attributed title, venue, publication-date, and type metadata.
0 public history versions across these dated registry records; status labels apply only to each cited observation.
Original-submission application metadata connected by exact reviewed active-ingredient names.
FDA- and HHS-attributed document metadata connected by exact reviewed peptide-name matches, with official GovInfo PDFs.
Selected records span September 12, 2003 to November 9, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.
These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.
Literature metadata
PubMed lists PMID 32725216 in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America as Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Equivalence Trial, with publication-date metadata of 2021-05-04 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 42869054 in The Lancet. Infectious diseases as Journal Article, Review, with publication-date metadata of 2026-10-13 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 33313994 in Clinical pharmacokinetics as Journal Article, Review, with publication-date metadata of 2020-12-14 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 33620544 in The Journal of membrane biology as Journal Article, Review, with publication-date metadata of 2021-02-23 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT03138733 at 2026-11-15T22:01:45.056Z. Its registry update date was 2026-10-07, and PeptideScanner's reviewed identity mapping was daptomycin.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT07148960 at 2026-11-15T22:01:45.056Z. Its registry update date was 2026-09-17, and PeptideScanner's reviewed identity mapping was daptomycin.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT05137119 at 2026-11-15T22:01:45.056Z. Its registry update date was 2026-05-06, and PeptideScanner's reviewed identity mapping was daptomycin.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT04983901 at 2026-11-15T22:01:45.056Z. Its registry update date was 2026-04-06, and PeptideScanner's reviewed identity mapping was daptomycin.↗
Literature metadata
PubMed lists PMID 41297715 in International journal of antimicrobial agents as Journal Article, Review, with publication-date metadata of 2025-11-24 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 41321327 in Critical reviews in analytical chemistry as Journal Article, Review, with publication-date metadata of 2025-12-01 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 39028390 in Infection as Systematic Review, Journal Article, Case Reports, with publication-date metadata of 2024-07-19 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 40558207 in Antibiotics (Basel, Switzerland) as Journal Article, Review, with publication-date metadata of 2025-06-18 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Citations
Numbered markers in the text point here. Each link opens the original public record.
DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026
U.S. Food and Drug Administration · Official source · Source checked November 15, 2026